Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurophysiol ; 98(4): 1988-96, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17652412

ABSTRACT

In spinal cats, locomotor recovery without rehabilitation is limited, but weight-bearing stepping returns with treadmill training. We studied whether neurotrophins administered to the injury site also restores locomotion in untrained spinal cats and whether combining both neurotrophins and training further improves recovery. Ordinary rat fibroblasts or a mixture of fibroblasts secreting brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) (Fb-NTF) were grafted into T12 spinal transection sites. Cats with each type of transplant were divided into two groups: one receiving daily training and the other receiving no training. As expected, trained cats with/without neurotrophin-producing transplants could step on the treadmill. Untrained cats without neurotrophin-producing transplants could not locomote. However, untrained cats with neurotrophin-secreting transplants performed plantar weight-bearing stepping at speeds up to 0.8 m/s as early as 2 wk after transection. Locomotor capability and stance lengths in these animals were similar to those in animals receiving training alone, suggesting that administration of BDNF/NT-3 was equivalent to treadmill training in restoring locomotion in chronically spinalized cats. Cats receiving both interventions showed the greatest improvement in step length. Anatomical evaluation indicated that all transections were complete and that axons did not enter the cord caudal to the graft. Thus BDNF/NT-3 secreting fibroblasts were equivalent to training in their ability to engage the locomotor circuitry in chronic spinal cats. Furthermore, the rapid time-course of recovery and the absence of axonal growth through the transplants indicate that the restorative mechanisms were not related to supraspinal axonal growth. Finally, the results show that transplants beneficial in rodents are applicable to larger mammals.


Subject(s)
Decerebrate State/drug therapy , Decerebrate State/physiopathology , Locomotion/physiology , Nerve Growth Factors/pharmacology , Animals , Biomechanical Phenomena , Brain-Derived Neurotrophic Factor/pharmacology , Cats , Data Interpretation, Statistical , Decerebrate State/therapy , Exercise Therapy , Female , Fibroblasts/drug effects , Fibroblasts/transplantation , Functional Laterality/physiology , Hindlimb/physiology , Immunohistochemistry , Neuronal Plasticity/drug effects , Neuronal Plasticity/physiology , Neurotrophin 3/pharmacology , Spinal Cord/cytology
2.
J Neurotrauma ; 22(1): 138-56, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15665609

ABSTRACT

Encapsulation of cells has the potential to provide a protective barrier against host immune cell interactions after grafting. Previously we have shown that alginate encapsulated BDNF-producing fibroblasts (Fb/BDNF) survived for one month in culture, made bioactive neurotrophins, survived transplantation into the injured spinal cord in the absence of immune suppression, and provided a permissive environment for host axon growth. We extend these studies by examining the effects of grafting encapsulated Fb/BDNF into a subtotal cervical hemisection on recovery of forelimb and hindlimb function and axonal growth in the absence of immune suppression. Grafting of encapsulated Fb/BDNF resulted in partial recovery of forelimb usage in a test of vertical exploration and of hindlimb function while crossing a horizontal rope. Recovery was significantly greater compared to animals that received unencapsulated Fb/BDNF without immune suppression, but similar to that of immune suppressed animals receiving unencapsulated Fb/BDNF. Immunocytochemical examination revealed neurofilament (RT-97), 5-HT, CGRP and GAP-43 containing axons surrounding encapsulated Fb/BDNF within the injury site, indicating axonal growth. BDA labeling however showed no evidence of regeneration of rubrospinal axons in recipients of encapsulated Fb/BDNF, presumably because the amounts of BDNF available from the encapsulated grafts are substantially less than those provided by the much larger numbers of Fb/BDNF grafted in a gelfoam matrix in the presence of immune suppression. These results suggest that plasticity elicited by the BDNF released from the encapsulated cells contributed to reorganization that led to behavioral recovery in these animals and that the behavioral recovery could proceed in the absence of rubrospinal tract regeneration. Alginate encapsulation is therefore a feasible strategy for delivery of therapeutic products produced by non-autologous engineered fibroblasts and provides an environment suitable for recovery of lost function in the injured spinal cord.


Subject(s)
Alginates , Biocompatible Materials , Cell Transplantation/methods , Fibroblasts/transplantation , Glucuronic Acid , Graft Rejection/prevention & control , Hexuronic Acids , Spinal Cord Injuries/surgery , Animals , Axons/physiology , Capsules , Cell Culture Techniques , Cervical Vertebrae , Female , Forelimb/physiology , Hindlimb/physiology , Nerve Regeneration/physiology , Rats , Rats, Sprague-Dawley , Recovery of Function/physiology , Spinal Cord Injuries/physiopathology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...